ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sitagliptin

Also written as “Sitagliptin”, “sitagliptin phosphate” and “Sitagliptin phosphate”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Glucose Intolerance · Renal Insufficiency · Hepatic Insufficiency, led by 11 companies.

Drug pageSitagliptin: every studyMany companies study it; this page follows only the 101 they lead. All 306 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 28, 2009101 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck780 open or runningphase 4since Jan 28, 2009Jul 2, 2004none ahead
Ono Pharmaceuticalits history only50 open or runningphase 3since Aug 11, 2006Aug 11, 2006none ahead
ADIUMits history only40 open or runningno phasesince Aug 10, 2026Aug 10, 2026none ahead
Novo Nordiskits history only40 open or runningphase 4since Jan 24, 2012Jun 18, 2008none ahead
Bio-innovaits history only22 open or runningphase 1since Dec 15, 2023Dec 15, 2023none ahead
Novartisits history only20 open or runningphase 4since Sep 13, 2012Jun 12, 2012none ahead
Profil Institut für Stoffwechselforschungits history only20 open or runningphase 2since Aug 28, 2013Aug 28, 2013none ahead
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 1since Jun 30, 2016Jun 30, 2016none ahead
Dong Wha Pharmaceuticalits history only10 open or runningphase 1since May 4, 2022May 4, 2022none ahead
Getz Pharmaits history only10 open or runningphase 4since Nov 29, 2021Nov 29, 2021none ahead

Also a collaborator on its studies: Parexel, Pfizer, Bristol-Myers Squibb and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Jan 3, 2007.

  1. Oct 27, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01462266 · 660 enrolled
  2. Nov 19, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01477853 · 166 enrolled
  3. Dec 1, 2011Phase 3 study in Diabetes MellitusNCT01485614 · 200 enrolled
  4. Mar 16, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01557504 · 25 enrolled
  5. Apr 19, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01582308 · 22 enrolled
  6. May 1, 20122 phase 3 studies in Diabetes Mellitus, Type 2NCT01590797, NCT01590771
  7. Aug 31, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01678820 · 299 enrolled
  8. Oct 4, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01702298 · 42 enrolled
  9. Jan 2, 2013Phase 3 study in Diabetes Mellitus, Type 2NCT01760447 · 223 enrolled
  10. Mar 25, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02099110 · 1,233 enrolled
  11. Dec 12, 2014Phase 4 study in Diabetes Mellitus, Type 2NCT02318693 · 53 enrolled
  12. Aug 25, 2015Phase 3 study in Diabetes Mellitus, Type 2NCT02532855 · 614 enrolled
  13. Apr 11, 2016Phase 3 study in Diabetes Mellitus, Type 2NCT02738879 · 746 enrolled
  14. Jun 1, 2016Phase 3 study in Diabetes Mellitus, Type 2NCT02791490 · 458 enrolled
  15. Jul 21, 2022Named sitagliptinINNProposed as its International Nonproprietary Name in WHO's List 127

TargetBeta

DPP4 →read by rule
“Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
LinagliptinruleBoehringer Ingelheimphase 496
gemigliptinruleLG Chemphase 430
anagliptinruleJW Pharmaceuticalphase 46
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

The newest 60 of 78 Merck leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT02791490Diabetes Mellitus, Type 23CompletedFeb 1, 2018458
NCT02738879Diabetes Mellitus, Type 23CompletedJan 22, 2018746
NCT02532855Diabetes Mellitus, Type 23CompletedOct 10, 2017614
NCT02318693Diabetes Mellitus, Type 24CompletedDec 15, 201553
NCT02099110Diabetes Mellitus, Type 23CompletedMay 26, 20161,233
NCT01760447Diabetes Mellitus, Type 23CompletedSep 17, 2019223
NCT01702298Diabetes Mellitus, Type 23CompletedMay 29, 201342
NCT01678820Diabetes Mellitus, Type 23TerminatedNov 1, 2013299
NCT01590797Diabetes Mellitus, Type 23CompletedJun 11, 2014467
NCT01590771Diabetes Mellitus, Type 23CompletedJun 10, 2014498
NCT01582308Diabetes Mellitus, Type 21CompletedDec 4, 201222
NCT01557504Diabetes Mellitus, Type 21CompletedApr 29, 201425
NCT01485614Diabetes Mellitus3CompletedOct 9, 2019200
NCT01477853Diabetes Mellitus, Type 23TerminatedDec 4, 2012166
NCT01462266Diabetes Mellitus, Type 23CompletedJun 6, 2013660
NCT01405911Glucose Intolerance2CompletedApr 9, 2012242
NCT01340768Diabetes Mellitus, Type 23CompletedSep 21, 2011870
NCT01296412Diabetes Mellitus, Type 23CompletedFeb 29, 2012653
NCT01189890Diabetes Mellitus, Type 23CompletedOct 31, 2012480
NCT01177384Diabetes Mellitus, Type 23CompletedMar 25, 2013380
NCT01131182Diabetes Mellitus, Type 24CompletedNov 4, 20101,147
NCT01093794Diabetes Mellitus, Type 21CompletedJun 201028
NCT01076088Diabetes Mellitus, Type 23CompletedDec 24, 2012744
NCT01076075Diabetes Mellitus, Type 23CompletedJul 11, 2011427
NCT01034111Diabetes Mellitus, Type 23CompletedOct 4, 201030
NCT01028391Diabetes Mellitus, Type 23CompletedJan 1, 2009317
NCT00993187Diabetes Mellitus, Type 24CompletedOct 29, 2013292
NCT00975052Diabetes Mellitus, Type 21CompletedMar 200616
NCT00944450Diabetes Mellitus, Type 21CompletedSep 200412
NCT00929201Diabetes Mellitus, Type 21CompletedMar 200861
NCT00888238Diabetes Mellitus, Type 21CompletedJun 10, 200912
NCT00885352Diabetes Mellitus, Type 23CompletedNov 10, 2010313
NCT00875394Diabetes Mellitus, Type 23CompletedJun 27, 200868
NCT00833027Diabetes Mellitus4CompletedOct 30, 2009608
NCT00832624Diabetes Mellitus, Type 24TerminatedSep 2, 200910
NCT00832390Diabetes Mellitus4CompletedJul 11, 200829
NCT00830076Diabetes Mellitus, Type 21CompletedApr 30, 200918
NCT00813995Diabetes Mellitus, Type 23CompletedAug 9, 2010395
NCT00790205Diabetes Mellitus, Type 23CompletedMar 30, 201514,671
NCT00758069Diabetes Mellitus, Type 22CompletedFeb 13, 200680
NCT00730275Diabetes Mellitus, Type 21CompletedDec 30, 201035
NCT00722371Diabetes Mellitus, Type 23CompletedOct 26, 20101,615
NCT00704132Diabetes Mellitus, Type 21CompletedApr 28, 201057
NCT00701090Diabetes Mellitus, Type 23CompletedOct 20091,035
NCT00696826Hepatic Insufficiency1CompletedMay 200420
NCT00642798Diabetes Mellitus, Type 21CompletedMar 200816
NCT00631488Diabetes Mellitus, Type 22CompletedJan 2009146
NCT00545584Diabetes Mellitus, Type 23CompletedNov 19, 20091,512
NCT00541775Diabetes Mellitus, Type 23CompletedMar 2007273
NCT00541450Diabetes Mellitus, Type 23CompletedJan 8, 2010492
NCT00541229Diabetes Mellitus, Type 21CompletedJun 17, 2008103
NCT00532935Diabetes Mellitus, Type 23CompletedOct 23, 2009517
NCT00511108Diabetes Mellitus, Type 21CompletedFeb 24, 2009211
NCT00509262Diabetes Mellitus, Type 23CompletedMar 16, 2011426
NCT00509236Diabetes Mellitus, Type 23CompletedMar 14, 2011129
NCT00482079Diabetes Mellitus, Type 22CompletedAug 25, 2004743
NCT00481663Diabetes Mellitus, Type 22CompletedJul 21, 2004555
NCT00482729Diabetes Mellitus, Type 23CompletedNov 3, 20081,246
NCT00449930Diabetes Mellitus, Type 23CompletedJul 25, 20081,050
NCT00418366Renal Insufficiency1CompletedMar 200324

How it is read

Names in the registry

  • “Sitagliptin”, 33 entries
  • “sitagliptin phosphate”, 18 entries
  • “sitagliptin”, 15 entries
  • “Sitagliptin phosphate”, 10 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: MK0431.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.